fig3

Figure 3. THZ2 and TMZ exhibit synergistic anti-GBM effects. (A and B) Effects of co-treatment with 0.1 μM THZ2 and 0.5 mM TMZ for 48 h on apoptosis in A172, U118MG, U87MG, and U251 cells. In panel (A), the tested THZ2 concentrations were 0.0625, 0.125, 0.25, 0.375, and 0.5 μM, respectively, and the TMZ concentrations were 0.5, 1, and 2 mM. Data are presented as mean ± SD from three independent experiments (n = 3). ns: No significant; ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. Statistical significance was determined using one-way ANOVA. TMZ: Temozolomide; GBM: glioblastoma; SD: standard deviation; ANOVA: analysis of variance.